Skin cancer and precancerous skin lesions
- Actinic keratosis (BAD, 2017)
- Basal cell carcinoma (BAD, 2021)
- Kaposi sarcoma (European consensus, 2019)
- Melanoma: Diagnostics (European consensus, 2022)
- Melanoma: Treatment (European consensus, 2022)
- Melanoma: Assessment and Management (NICE, 2015 (updated 2022))
- Melanoma (BAD and Royal College of Physicians, 2007)
- Primary cutaneous lymphomas (BAD, 2018)
- Squamous cell carcinoma (BAD, 2020)
- Squamous cell carcinoma in situ (BAD, 2022)
- Squamous cell carcinoma in solid organ transplant recipients (Stasko, et al., 2004)
Skin cancer prevention and surveillance
- Skin cancer advice for organ transplant recipients (BAD, 2024)
- Prevention of SCC in solid organ transplant recipients (International Delphi Consensus, 2017)
- Skin cancer prevention (NICE, 2011 (updated 2016)
- Skin cancer surveillance in solid organ transplant recipients (US Delphi Consensus, 2019)
- Sunlight exposure: risks and benefits (NICE, 2016)
Cutaneous infection
Skin Toxicities associated with Cancer Treatments
- Common Terminology Criteria for Adverse Events Grading and Management Escalation Pathway
- Skin toxicities related to anticancer agents (Lacouture, et al., 2020)
- Skin toxicities related to immune checkpoint inhibitors (Kawsar, et al., 2023)
- Immunotherapy Cutaneous Toxicity Guidelines (Kindly provided by Dr Andy Muinonen-Martin (Leeds Teaching Hospital), with Melanoma Focus guidelines due to be published this year.)